Substance
CETUXIMAB
Global reference: every product and company linked to this substance.
- cas: 205923-56-4
- ncit: C1723
- rxnorm: 318341
- unii: PQX0D8J21J
C-225 · C225 · CETUXIMAB (GENETICAL RECOMBINATION) [JAN] · cetuximab [INN] · CETUXIMAB [JAN] · CETUXIMAB [USAN] · Cetuximab [WHO-DD] · ERBITUX · IMC-225 · IMC-C225 · IMCC-225 · IMCC225
Revenue by product (2)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| ELI LILLY AND COMPANY COMMON STOCK | ERBITUX | Q4 2024 | $175.0M |
| ELI LILLY AND COMPANY COMMON STOCK | ERBITUX | Q4 2024 | $175.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (2)
- ERBITUX · ELI LILLY AND COMPANY COMMON STOCK
- ERBITUX · ELI LILLY AND COMPANY COMMON STOCK